Otonomy, Inc. (OTIC) Stock Analysis
DELISTED 2023
What happened to Otonomy, Inc. (OTIC) stock?
Otonomy, Inc. (OTIC) no longer trades on public markets. It was delisted in April 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Otonomy, Inc. (OTIC) trades at $0.0085. Otonomy, Inc. is a biopharmaceutical company focused on developing therapeutics for neurotology. Their pipeline includes treatments for tinnitus, hearing loss, and other related conditions, primarily in Phase II clinical trials. Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for OTIC: OTIC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OTIC against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Otonomy, Inc. (OTIC) Healthcare & Pipeline Overview
Otonomy, Inc. is a biopharmaceutical company specializing in neurotology therapeutics, addressing conditions like tinnitus and hearing loss. Their pipeline focuses on sustained-exposure formulations and gene therapies, with key products in Phase II clinical trials, positioning them in a competitive biotechnology landscape.
What Is the Investment Thesis for OTIC?
Otonomy, Inc. presents a high-risk, high-reward investment opportunity within the neurotology therapeutics space. The company's focus on inner ear disorders addresses a significant unmet medical need. Successful completion of Phase II trials for OTO-313 and OTO-413 could serve as major catalysts, driving significant value appreciation. These trials are expected to yield results within the next 12-18 months. The company's pipeline, including gene therapy programs like OTO-825, offers long-term growth potential. However, the company's negative profit margin of -40260.0% and gross margin of -196.0% highlight substantial financial risks. The company's high beta of 1.57 suggests significant volatility relative to the market. Investors should carefully weigh the potential for clinical success against the inherent risks of biotechnology investments.
Based on FMP financials and quantitative analysis
OTIC Key Highlights
Otonomy, Inc. is focused on developing therapeutics for neurotology, addressing conditions like tinnitus and hearing loss.
- OTO-313, a sustained-exposure formulation of gacyclidine, is in Phase II clinical trials for tinnitus.
- OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor, is in Phase IIa clinical trials for cochlear synaptopathy.
- The company has a negative profit margin of -40260.0%, indicating significant losses.
- The company's dividend yield is 1294.12%.
Who Are OTIC's Competitors?
OTIC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PHIO Phio Pharmaceuticals Corp. | $1.21 | +5.22% | $14.1M | 30 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
| NBIX Neurocrine Biosciences, Inc. | $153.42 | -1.37% | $15.4B | 93 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OTIC's Key Strengths?
Pipeline of product candidates targeting unmet needs in neurotology.
- Proprietary sustained-exposure drug delivery technology.
- Strategic collaborations with universities and other companies.
- Focus on innovative therapies for hearing loss and tinnitus.
What Are OTIC's Weaknesses?
Significant operating losses and negative profit margin.
- Reliance on successful clinical trial outcomes.
- Limited commercialized products and revenue streams.
- High cash burn rate.
What Could Drive OTIC Stock Higher?
OTIC catalyst: Phase II clinical trial results for OTO-313 in tinnitus (expected in the next 12-18 months).
- Phase IIa clinical trial results for OTO-413 in cochlear synaptopathy (expected in the next 12-18 months).
- Continued development of OTO-510 for the prevention of cisplatin-induced hearing loss.
- Advancement of OTO-825, a gene therapy for congenital hearing loss, through preclinical and clinical studies.
- Progress in the OTO-6XX program focused on hair cell regeneration for severe hearing loss.
What Are the Key Risks for OTIC?
Financial-distress signal — its Altman Z-Score of -16.93 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to achieve positive results in clinical trials for OTO-313 and OTO-413.
- Regulatory delays or rejection of product candidates.
- Competition from other companies developing therapies for hearing loss and tinnitus.
- Dependence on securing additional funding to support research and development activities.
- Patent challenges or expirations that could impact market exclusivity.
What Are the Growth Opportunities for OTIC?
- Advancement of OTO-313 for Tinnitus Treatment: Otonomy's OTO-313, currently in Phase II clinical trials, targets tinnitus, a condition with a substantial market size. Positive Phase II results could lead to partnerships or further funding, accelerating development and commercialization. The timeline for potential market entry is dependent on successful trial outcomes and regulatory approvals, potentially within the next 3-5 years.
- Development of OTO-413 for Hearing Loss: OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF), is in Phase IIa clinical trials for cochlear synaptopathy and speech-in-noise hearing difficulties. The hearing loss therapeutics market is substantial, driven by an aging population. Successful clinical trials could position Otonomy as a leader in addressing this unmet need. Market entry could be possible within 3-5 years pending positive trial data and regulatory approvals.
- Gene Therapy Program for Congenital Hearing Loss (OTO-825): Otonomy's OTO-825 represents a long-term growth opportunity in gene therapy for congenital hearing loss. The market for gene therapies is rapidly expanding, with significant potential for addressing genetic disorders. While still in early stages, successful development could lead to a valuable asset and potential partnerships. This program has a longer timeline, potentially 5-7 years before market entry.
- Expansion of Otoprotectant Portfolio (OTO-510): Otonomy is developing OTO-510 as an otoprotectant for the prevention of cisplatin-induced hearing loss. This addresses a specific need in cancer treatment, where cisplatin can cause hearing damage. Successful development and commercialization could provide a niche market opportunity. Market entry could be possible within 3-5 years pending positive trial data and regulatory approvals.
- Hair Cell Regeneration Program (OTO-6XX): Otonomy's OTO-6XX program focuses on inducing hair cell repair and regeneration for the treatment of severe hearing loss. This represents a potentially transformative approach to hearing loss treatment. While still in early stages, successful development could revolutionize the field. This program has a longer timeline, potentially 5-7 years before market entry.
What Opportunities Does OTIC Have?
- Positive clinical trial results for OTO-313 and OTO-413.
- Partnerships for commercialization of product candidates.
- Expansion of pipeline through internal research and development.
- Acquisition of complementary technologies or companies.
What Are OTIC's Competitive Advantages?
- Proprietary formulations and drug delivery technologies.
- Patent protection for key product candidates.
- Clinical trial data supporting efficacy and safety.
- Strategic collaborations with universities and other companies.
What Does OTIC Do?
Otonomy, Inc., founded in 2008 and headquartered in San Diego, California, is a biopharmaceutical company dedicated to developing innovative therapeutics for neurotology, the branch of medicine focused on the ear and related structures. The company's mission is to address unmet medical needs in the treatment of hearing loss, tinnitus, and other inner ear disorders. Otonomy's pipeline includes several product candidates, such as OTO-313, a sustained-exposure formulation of gacyclidine, currently in Phase II clinical trials for the treatment of tinnitus. Another key asset is OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF), also in Phase IIa clinical trials, targeting cochlear synaptopathy and speech-in-noise hearing difficulties. In addition to these clinical-stage programs, Otonomy is developing OTO-510, an otoprotectant designed to prevent cisplatin-induced hearing loss, and OTO-825, a gene therapy for congenital hearing loss. Furthermore, OTO-6XX is being developed to induce hair cell repair and regeneration for severe hearing loss. Otonomy has established strategic collaborations to advance its research and development efforts, including license agreements with the University of California and DURECT Corporation, and a collaboration with Applied Genetic Technologies Corporation for gene therapy development. The company operates primarily in the United States.
What Products and Services Does OTIC Offer?
- Develop therapeutics for neurotology, focusing on inner ear disorders.
- Offer OTO-313, a treatment for tinnitus currently in Phase II clinical trials.
- Develop OTO-413 for cochlear synaptopathy and speech-in-noise hearing difficulties, also in Phase IIa trials.
- Develop OTO-510, an otoprotectant for cisplatin-induced hearing loss.
- Work on OTO-825, a gene therapy for congenital hearing loss.
- Research OTO-6XX to induce hair cell repair and regeneration for severe hearing loss.
How Does OTIC Make Money?
- Develop and commercialize therapeutics for neurotology.
- Out-license or partner for commercialization of products.
- Generate revenue through product sales and licensing agreements.
- Invest heavily in research and development of new therapies.
What Industry Does OTIC Operate In?
Otonomy, Inc. operates within the biotechnology industry, specifically targeting the neurotology market. This market is characterized by a growing prevalence of hearing loss and tinnitus, driven by factors such as aging populations and noise exposure. The competitive landscape includes companies like BIOC, BLCM, INFIQ, PHGE, and PHIO, which are developing various treatments for hearing disorders. The biotechnology industry is known for its high-risk, high-reward nature, with significant investments required for research and development and regulatory approvals. The success of companies like Otonomy depends on their ability to innovate and bring effective therapies to market.
Who Are OTIC's Key Customers?
- Patients suffering from tinnitus, hearing loss, and other inner ear disorders.
- Healthcare providers who prescribe and administer Otonomy's therapies.
- Hospitals and clinics that use Otonomy's products.
- Potential pharmaceutical partners for licensing and commercialization.
Key Financial Metrics
Return on equity for Otonomy, Inc. stands at 9.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -52.6%, showing how much profit it generates from its asset base. A current ratio of 6.52 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
Otonomy, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO David M. Maggio. OTIC has traded publicly since 2014.
Financial Health
Otonomy, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -16.93 places it in the distress zone, a signal of elevated financial risk.
OTIC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Otonomy's recent insider buying suggests those in the know see potential upside, boosting confidence in the company's future prospects.
- The community sentiment appears to be cautiously optimistic, with discussions focusing on potential catalysts and upcoming milestones.
- Market perception seems to be shifting, with some analysts highlighting Otonomy's niche focus in addressing unmet needs in the hearing loss space.
- Positive clinical trial updates, even if preliminary, could significantly alter market perception and drive investor interest.
Bear Case
- Community chatter reveals concerns about Otonomy's cash runway, prompting questions about potential dilution or financing strategies.
- Despite some positive sentiment, a significant portion of the community remains skeptical, citing past disappointments and unmet expectations.
- Market perception is still largely negative, with Otonomy struggling to overcome its history of clinical setbacks and commercial challenges.
- Recent insider selling, even if for personal reasons, could dampen investor enthusiasm and raise concerns about the company's near-term outlook.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
OTIC Latest News
No recent news available for OTIC.
Leadership: David M. Maggio
CEO
David M. Maggio serves as the CEO of Otonomy, Inc., bringing extensive experience in the biopharmaceutical industry. His career spans various leadership roles in corporate development, commercial operations, and strategic planning. Before joining Otonomy, he held positions at leading pharmaceutical companies, contributing to product launches and market access strategies. Maggio's background includes a strong foundation in finance and business administration, providing a comprehensive perspective on company management and growth.
Track Record: Under David Maggio's leadership, Otonomy has focused on advancing its clinical pipeline, particularly OTO-313 and OTO-413, through key clinical trial milestones. He has also overseen strategic collaborations to expand the company's research and development capabilities. His tenure has been marked by efforts to secure funding and manage the company's financial resources amidst ongoing clinical development programs.
What Investors Ask About Otonomy, Inc. (OTIC) — Healthcare
What happened to Otonomy, Inc. (OTIC) stock?
Otonomy, Inc. (OTIC) no longer trades on public markets. It was delisted in April 2023. The figures below are historical and are not a current quote.
Can I still buy OTIC shares?
No. OTIC stopped trading on public markets in April 2023, so the shares are not available through a broker. Anything you see quoted for OTIC elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before OTIC stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Otonomy, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Otonomy, Inc. do?
Otonomy, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for neurotology, which is the branch of medicine focused on the ear, nose, and throat. The company's primary focus is on developing treatments for inner ear disorders, including hearing loss, tinnitus, and other related conditions.
What do analysts say about OTIC stock?
Analyst coverage of Otonomy, Inc. (OTIC) is limited, reflecting the company's size and stage of development. The consensus view is that OTIC represents a high-risk, high-reward investment opportunity. Key valuation metrics are difficult to assess due to the company's current lack of profitability.
What are the main risks for OTIC?
Otonomy, Inc. faces several key risks inherent to the biotechnology industry. Clinical trial risk is paramount, as the success of its product candidates depends on positive trial outcomes. Regulatory risk is also significant, as the company must navigate complex approval processes. Financial risk is a concern, given the company's history of operating losses and reliance on external funding.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending and may provide further insights.
- Financial data is based on the most recently available information.
- Clinical trial timelines are subject to change.